3SBIO (01530) · Company profile · Eqvero

3SBIO

01530HKEX

Unit: CNY	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	17.7 bn CNY	9.11 bn CNY	7.82 bn CNY	6.86 bn CNY	6.38 bn CNY
Cost of revenue	818.01 m CNY	884.65 m CNY	839.45 m CNY	805.48 m CNY	777.28 m CNY
Research and development expense	1.52 bn CNY	1.33 bn CNY	794.79 m CNY	693.17 m CNY	753.87 m CNY
Selling, general and administrative expense	4.28 bn CNY	3.85 bn CNY	3.49 bn CNY	2.96 bn CNY	2.7 bn CNY
Operating profit after depreciation	10.49 bn CNY	2.61 bn CNY	1.92 bn CNY	1.91 bn CNY	1.69 bn CNY
Operating profit before depreciation	11.02 bn CNY	3.01 bn CNY	2.25 bn CNY	2.29 bn CNY	2.02 bn CNY
EBIT	10.49 bn CNY	2.61 bn CNY	1.92 bn CNY	1.91 bn CNY	1.69 bn CNY
EBITDA	11.02 bn CNY	3.01 bn CNY	2.25 bn CNY	2.29 bn CNY	2.02 bn CNY
Interest expense	76.39 m CNY	190.85 m CNY	212.3 m CNY	101.05 m CNY	66.53 m CNY
Profit before tax	10.75 bn CNY	2.72 bn CNY	1.98 bn CNY	2.27 bn CNY	1.87 bn CNY
Income tax expense	1.65 bn CNY	500.54 m CNY	392.17 m CNY	366.02 m CNY	241.19 m CNY
Income before extraordinary items	8.48 bn CNY	2.09 bn CNY	1.55 bn CNY	1.91 bn CNY	1.65 bn CNY

Quotes are end-of-day data. Content is for research purposes and is not investment advice.